# HLB Group to acquire 28.25% stake in PSMC for CAR-T drug development

HLB Group subsidiaries will acquire 30 billion won ($22.8 million) worth of equity in PSMC, a lead frame manufacturer, making HLB the largest shareholder with a 28.25% stake. PSMC will change its name to HLB innovation and add biopharmaceutical lines to develop CAR-T treatments.

- Type: Acquisition
- Announced: 2023-02-27
- Where: South Korea
- Value: $22.8M (30.0B KRW)
- Status: announced
- Products: lead frames, CAR-T treatments
- Sectors: [Semiconductors and Industrial Electronics](https://endata.com/sectors/semiconductors-electronics.md)

## Companies

- [HLB Group](https://endata.com/companies/68798.md) (acquirer)
- [HLB Group](https://endata.com/companies/68798.md) (investor)
- [PSMC](https://endata.com/companies/68799.md) (target)
- [HLB Life Science](https://endata.com/companies/68800.md) (investor)
- [HLB Pharm](https://endata.com/companies/68801.md) (investor)
- [HLB Therapeutics](https://endata.com/companies/68802.md) (investor)
- [HLB Investment](https://endata.com/companies/68803.md) (investor)

## Sources

- [koreabiomed.com](https://www.koreabiomed.com/news/articleView.html?idxno=20534), 2023-02-27: "The HLB Group expressed its intention to acquire PSMC’s equity worth 30 billion won ($22.8 million) on Feb. 1."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.